# Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia

> **NCT05936489** · PHASE1 · COMPLETED · sponsor: **LENZ Therapeutics, Inc** · enrollment: 30 (actual)

## Conditions studied

- Eye Diseases
- Presbyopia
- Refractive Errors
- Brimonidine Tartrate
- Aceclidine
- Ophthalmic Solutions

## Interventions

- **DRUG:** Aceclidine + Brimonidine
- **DRUG:** Aceclidine

## Key facts

- **NCT ID:** NCT05936489
- **Lead sponsor:** LENZ Therapeutics, Inc
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-06
- **Primary completion:** 2023-10-03
- **Final completion:** 2023-10-03
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05936489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05936489, "Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05936489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*